Leiomyosarcoma future or investigational therapies: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
| Line 3: | Line 3: | ||
Following are some recently approved drugs in the treatment of the leimyosarcoma. | Following are some recently approved drugs in the treatment of the leimyosarcoma. | ||
* Trabectedin was approved as a chemotherapy for leiomyosarcoma that cannot be operated or for the patients that previously underwent treatment with anthracycline. Trabectedin exerts its chemotherapeutic effect by alkylation and damages the DNA of cells, which prevents them from dividing, and causes them to die.<ref name="pmid25048043">Brodowicz T (2014) [https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&retmode=ref&cmd=prlinks&id=25048043 Trabectedin in soft tissue sarcomas.] ''Future Oncol'' 10 (8 Suppl):s1-5. [http://dx.doi.org/10.2217/fon.14.117 DOI:10.2217/fon.14.117] PMID: [https://pubmed.gov/25048043 25048043]</ref> | * Trabectedin was approved as a chemotherapy for leiomyosarcoma that cannot be operated or for the patients that previously underwent treatment with anthracycline. Trabectedin exerts its chemotherapeutic effect by alkylation and damages the DNA of cells, which prevents them from dividing, and causes them to die.<ref name="pmid25048043">Brodowicz T (2014) [https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&retmode=ref&cmd=prlinks&id=25048043 Trabectedin in soft tissue sarcomas.] ''Future Oncol'' 10 (8 Suppl):s1-5. [http://dx.doi.org/10.2217/fon.14.117 DOI:10.2217/fon.14.117] PMID: [https://pubmed.gov/25048043 25048043]</ref> | ||
* Pazopanib, an oral therapy approved for leiomyosarcoma, is often combined with chemotherapy and/or radiation therapy.It works as a potent and selective multi-targeted receptor tyrosine kinase inhibitor that blocks tumour growth and inhibits angiogenesis. | * Pazopanib, an oral therapy approved for leiomyosarcoma, is often combined with chemotherapy and/or radiation therapy.It works as a potent and selective multi-targeted receptor tyrosine kinase inhibitor that blocks tumour growth and inhibits angiogenesis.<ref name="pmid22595799">van der Graaf WT, Blay JY, Chawla SP, Kim DW, Bui-Nguyen B, Casali PG et al. (2012) [https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&retmode=ref&cmd=prlinks&id=22595799 Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial.] ''Lancet'' 379 (9829):1879-86. [http://dx.doi.org/10.1016/S0140-6736(12)60651-5 DOI:10.1016/S0140-6736(12)60651-5] PMID: [https://pubmed.gov/22595799 22595799]</ref> | ||
* Currently, there are many investigational studies are going on to identify other agents that may prove useful in the treatment of Leiomyosarcoma.Clinical trials are testing new drugs to see if they're safe and if they work. | * Currently, there are many investigational studies are going on to identify other agents that may prove useful in the treatment of Leiomyosarcoma.Clinical trials are testing new drugs to see if they're safe and if they work. | ||
Revision as of 05:24, 10 June 2018
Following are some recently approved drugs in the treatment of the leimyosarcoma.
- Trabectedin was approved as a chemotherapy for leiomyosarcoma that cannot be operated or for the patients that previously underwent treatment with anthracycline. Trabectedin exerts its chemotherapeutic effect by alkylation and damages the DNA of cells, which prevents them from dividing, and causes them to die.[1]
- Pazopanib, an oral therapy approved for leiomyosarcoma, is often combined with chemotherapy and/or radiation therapy.It works as a potent and selective multi-targeted receptor tyrosine kinase inhibitor that blocks tumour growth and inhibits angiogenesis.[2]
- Currently, there are many investigational studies are going on to identify other agents that may prove useful in the treatment of Leiomyosarcoma.Clinical trials are testing new drugs to see if they're safe and if they work.
References
- ↑ Brodowicz T (2014) Trabectedin in soft tissue sarcomas. Future Oncol 10 (8 Suppl):s1-5. DOI:10.2217/fon.14.117 PMID: 25048043
- ↑ van der Graaf WT, Blay JY, Chawla SP, Kim DW, Bui-Nguyen B, Casali PG et al. (2012) Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet 379 (9829):1879-86. DOI:10.1016/S0140-6736(12)60651-5 PMID: 22595799